Skip to main content
. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612

Table 1.

Comparative analyses of pharmacokinetics, dosage, and formulations of rimegepant, ubrogepant, and atogepant.

Drugs Rimegepant Ubrogepant Atogepant
Other names BHV-3000, BMS-927711 MK-1602 AGN-241689, MK-8031
Trade name Nurtec®, Nurtec ODT®, Vydura® Ubrelvy® Qulipta®
Marketed Biohaven Pharmaceuticals, Pfizer Allergan Pharmaceuticals Allergan Pharmaceuticals
FDA approval February 2020 (acute); May 2021 (prevention) December 2019 September 2021
Molecule graphic file with name brainsci-12-01612-i001.jpg graphic file with name brainsci-12-01612-i002.jpg graphic file with name brainsci-12-01612-i003.jpg
Indication Acute treatment of migraine with or without aura in adults. Preventive treatment of episodic migraine in adults Acute treatment of migraine with or without aura in adults Preventive treatment of episodic migraine in adults
Dose 75 mg PO as needed. Not to exceed 75 mg/ 24 h. Safety of >18 doses/30 days has not been established 50 or 100 mg PO as needed. If needed, may take second dose at least 2 hrs after initial dose. Not to exceed 200 mg/24 h. Safety of treating >8 migraines/30 days has not been established 10, 30, or 60 mg PO
Dose adjustments Renal impairment (CrCl < 15 mL/min); hepatic impairment (Child–Pugh > C); drug interactions Renal impairment (CrCl < 30 mL/min); hepatic impairment (Child–Pugh ≥ C); drug interactions Renal impairment (CrCl < 30 mL/min); hepatic impairment (Child–Pugh ≥ C); drug interactions
Route of administration Oral Oral Oral
Contraindications History of hypersensitivity Concomitant use with strong CYP3A4 inhibitors None
Adverse effects Nausea (2%), hypersensitivity (including delayed) Nausea (2–4%), somnolence (2–3%), dry mouth (2%) Nausea (5–9%), constipation (6%), somnolence (4–6%), elevated AST/ALT (1%)
Pregnancy and lactation Data not available Data not available Data not available
Pediatric Data not available Data not available Data not available
Considerations Orally disintegrating tablet. It can be swallowed without additional liquid High-fat meal delayed plasma concentration High-fat meal effect was not significant.